Karyopharm Therapeutics (KPTI) Tops Q1 EPS by 1c, reaffirms guidance

Karyopharm Therapeutics (NASDAQ: KPTI) reported Q1 EPS of ($0.32), $0.01 better than the analyst estimate of ($0.33). Revenue for the quarter came in at $33.1 million versus the consensus estimate of $35.86 million.

GUIDANCE:

Karyopharm Therapeutics sees Q2 2024 revenue of $140-160 million, versus the consensus of $146.5 million.

For earnings history and earnings-related data on Karyopharm Therapeutics (KPTI) click here.

You May Also Be Interested In

• BofA raises AMD target to $720, sees server CPU TAM tripling to $211B by 2030
• Rithm Capital earns S&P upgrade to ’B+’ following steady revenue diversification
• Cracker Barrel (CBRL) Tops Q4 EPS by 89c, Offers Guidance